Syndax Pharmaceuticals Income Statement (2015-2025) | SNDX

1Y3Y5Y7Y10YAll
Download Data
Income Statement Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.30M0.30M0.30M0.30M0.30M0.30M0.30M0.30M0.30M1.19M0.38M0.38M0.38M0.38M0.38M0.38M0.38M0.38M0.38M0.38M0.38M0.38M
Operating items
Research & Development 1.72M2.97M2.59M4.79M6.13M12.27M8.47M9.55M9.86M12.19M16.60M15.34M14.85M14.10M15.82M11.28M12.29M9.92M9.50M9.56M10.94M14.41M15.52M
Selling, General & Administrative 2.71M3.19M2.40M4.27M2.81M3.27M2.97M3.93M4.29M3.56M4.08M4.79M4.48M4.12M3.89M3.91M3.46M3.60M5.08M5.92M6.05M5.82M4.72M
Operating Expenses 4.43M6.16M4.98M9.06M8.94M15.54M11.45M13.48M14.15M15.75M20.68M20.13M19.33M18.22M19.71M15.19M15.75M13.53M14.59M15.48M16.99M20.23M20.24M
Operating Income -4.43M-5.86M-4.68M-8.75M-8.63M-15.24M-11.14M-13.18M-13.84M-15.45M-19.49M-19.75M-18.95M-17.84M-19.33M-14.81M-15.37M-13.15M-14.21M-15.10M-16.61M-19.85M-19.86M
EBIT -4.43M-5.86M-4.68M-8.75M-8.63M-15.24M-11.14M-13.18M-13.84M-15.45M-19.49M-19.75M-18.95M-17.84M-19.33M-14.81M-15.37M-13.15M-14.21M-15.10M-16.61M-19.85M-19.86M
Non-operating items
Interest & Investment Income -0.34M-0.23M-0.52M0.14M0.28M0.27M0.27M0.26M0.29M0.41M0.46M
Other Non Operating Income -0.01M-0.04M0.01M-0.02M0.00M0.06M-0.05M-0.09M-0.05M-0.08M
Non Operating Income -0.48M-1.87M-0.58M-1.58M0.28M0.27M0.33M0.21M0.20M0.36M0.39M0.35M0.56M0.50M0.50M0.51M0.46M0.32M0.20M-0.14M-0.45M-0.58M-0.56M
Net income details
EBT -4.77M-6.09M-5.20M-8.61M-8.36M-14.97M-10.87M-12.92M-13.55M-15.04M-19.03M-19.75M-18.95M-17.84M-19.33M-14.81M-15.37M-13.15M-14.21M-15.10M-16.61M-19.85M-19.86M
Profit After Tax -4.91M-7.73M-5.26M-10.33M-8.36M-14.97M-10.81M-12.97M-13.64M-15.09M-19.10M-19.40M-18.39M-17.34M-18.84M-14.30M-14.92M-12.83M-14.00M-15.24M-17.06M-20.44M-20.42M
Income from Continuing Operations -4.77M-6.09M-5.20M-8.61M-8.36M-14.97M-10.87M-12.92M-13.55M-15.04M-19.03M-19.75M-18.95M-17.84M-19.33M-14.81M-15.37M-13.15M-14.21M-15.10M-16.61M-19.85M-19.86M
Consolidated Net Income -4.77M-6.09M-5.20M-8.61M-8.36M-14.97M-10.87M-12.92M-13.55M-15.04M-19.03M-19.75M-18.95M-17.84M-19.33M-14.81M-15.37M-13.15M-14.21M-15.10M-16.61M-19.85M-19.86M
Income towards Parent Company -4.77M-6.09M-5.20M-8.61M-8.36M-14.97M-10.87M-12.92M-13.55M-15.04M-19.03M-19.75M-18.95M-17.84M-19.33M-14.81M-15.37M-13.15M-14.21M-15.10M-16.61M-19.85M-19.86M
Net Income towards Common Stockholders -4.77M-6.09M-5.20M-8.61M-8.36M-14.97M-10.87M-12.92M-13.55M-15.04M-19.03M-19.75M-18.95M-17.84M-19.33M-14.81M-15.37M-13.15M-14.21M-15.10M-16.61M-19.85M-19.86M
Additional items
EPS (Basic) -208.78-790.85-105.57-2.85-0.47-0.84-0.59-2.85-0.47-0.84-0.800.790.740.680.70-0.53-0.47-0.41-0.44-0.56-0.42-0.46-0.44
Shares Outstanding (Weighted Average) 17.37M17.78M17.78M18.19M18.19M18.24M18.26M22.22M24.39M24.70M24.71M23.36M24.84M25.00M27.10M27.14M27.14M30.24M36.09M40.87M40.87M48.24M48.25M48.63M49.39M55.01M56.23M60.22M68.44M68.82M69.48M69.64M69.64M84.97M84.99M85.10M85.36M86.02M86.05M86.14M
EBITDA -4.91M-5.86M-4.68M-10.13M-8.39M-15.06M-11.14M-13.03M-13.60M-15.10M-19.49M-19.75M-18.95M-17.84M-19.33M-14.81M-15.37M-13.15M-14.21M-15.10M-16.61M-19.85M-19.86M
Shares Outstanding 0.70M17.77M17.77M18.18M18.22M22.22M22.31M24.39M24.70M22.71M24.05M24.84M27.10M27.12M27.14M27.14M30.24M38.51M38.83M47.88M48.25M48.62M48.85M54.98M55.03M56.40M60.12M68.11M68.50M69.43M69.64M84.83M84.98M85.03M85.29M85.69M86.05M86.06M86.91M